Tesamorelin: the approved GHRH analogue for visceral fat
Tesamorelin is a synthetic analog of GHRH (Growth Hormone-Releasing Hormone) with a prolonged half-life, approved by the FDA under the name Egrifta for visceral lipoatrophy. Its precise mechanism of action on the GH/IGF-1 axis and its robust clinical data make it a reference compound for research on visceral adipose metabolism.
